Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment

Miriam  Kolko; Gus Gazzard; Christophe Baudouin; Sofie Beier; Françoise Brignole-Baudouin; Barbara Cvenkel; Fredrik  Fineide; Anne Hedengran; Anton Hommer; Erik Jespersen; Elisabeth M. Messmer; Rachna Murthy; Amy Gallant Sullivan; Andrew J. Tatham; Tor Paaske Utheim; Marijke Vittrup; David A. Sullivan

doi:https://doi.org/10.1016/j.jtos.2023.05.012

Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment

Miriam Kolko, Gus Gazzard, Christophe Baudouin, Sofie Beier, Françoise Brignole-Baudouin, Barbara Cvenkel, Fredrik Fineide, Anne Hedengran, Anton Hommer, Erik Jespersen, Elisabeth M. Messmer, Rachna Murthy, Amy Gallant Sullivan, Andrew J. Tatham, Tor Paaske Utheim, Marijke Vittrup, David A. Sullivan

Publications: Contribution to journal › Journal article › Research › peer-review

Abstract

Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy. This meeting focused on the impact of glaucoma medications on the ocular surface, and how OSD can influence glaucoma treatment. The term “ocular surface” encompasses the surface (cornea and conjunctiva), tear film, and adnexa (lacrimal and meibomian glands). The speakers included internationally renowned glaucoma and OSD experts. The evidence-based proceedings of this meeting are presented in this TFOS Experts' Meeting report.

Original language	English
Journal	The Ocular Surface
Pages (from-to)	456–468
Number of pages	13
ISSN	1542-0124
DOIs	https://doi.org/10.1016/j.jtos.2023.05.012
Publication status	Published - Jul 2023

Keywords

low vision
glaucoma
medication packaging

Artistic research

No

Access to Document

https://doi.org/10.1016/j.jtos.2023.05.012

Cite this

Kolko, M., Gazzard, G., Baudouin, C., Beier, S., Brignole-Baudouin, F., Cvenkel, B., Fineide, F., Hedengran, A., Hommer, A., Jespersen, E., Messmer, E. M., Murthy, R., Sullivan, A. G., Tatham, A. J., Utheim, T. P., Vittrup, M., & Sullivan, D. A. (2023). Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment. The Ocular Surface, 456–468. https://doi.org/10.1016/j.jtos.2023.05.012

@article{173dc258a753429781afdfde92dea92e,

title = "Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment",

abstract = "Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy. This meeting focused on the impact of glaucoma medications on the ocular surface, and how OSD can influence glaucoma treatment. The term “ocular surface” encompasses the surface (cornea and conjunctiva), tear film, and adnexa (lacrimal and meibomian glands). The speakers included internationally renowned glaucoma and OSD experts. The evidence-based proceedings of this meeting are presented in this TFOS Experts' Meeting report.",

keywords = "low vision, glaucoma, medication packaging",

author = "Miriam Kolko and Gus Gazzard and Christophe Baudouin and Sofie Beier and Fran{\c c}oise Brignole-Baudouin and Barbara Cvenkel and Fredrik Fineide and Anne Hedengran and Anton Hommer and Erik Jespersen and Messmer, {Elisabeth M.} and Rachna Murthy and Sullivan, {Amy Gallant} and Tatham, {Andrew J.} and Utheim, {Tor Paaske} and Marijke Vittrup and Sullivan, {David A.}",

year = "2023",

month = jul,

doi = "https://doi.org/10.1016/j.jtos.2023.05.012",

language = "English",

pages = "456–468",

journal = "The Ocular Surface",

issn = "1542-0124",

publisher = "Elsevier Inc.",

}

Kolko, M, Gazzard, G, Baudouin, C, Beier, S, Brignole-Baudouin, F, Cvenkel, B, Fineide, F, Hedengran, A, Hommer, A, Jespersen, E, Messmer, EM, Murthy, R, Sullivan, AG, Tatham, AJ, Utheim, TP, Vittrup, M & Sullivan, DA 2023, 'Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment', The Ocular Surface, pp. 456–468. https://doi.org/10.1016/j.jtos.2023.05.012

TY - JOUR

T1 - Impact of glaucoma medications on the ocular surface and how ocular surface disease can influence glaucoma treatment

AU - Kolko, Miriam

AU - Gazzard, Gus

AU - Baudouin, Christophe

AU - Beier, Sofie

AU - Brignole-Baudouin, Françoise

AU - Cvenkel, Barbara

AU - Fineide, Fredrik

AU - Hedengran, Anne

AU - Hommer, Anton

AU - Jespersen, Erik

AU - Messmer, Elisabeth M.

AU - Murthy, Rachna

AU - Sullivan, Amy Gallant

AU - Tatham, Andrew J.

AU - Utheim, Tor Paaske

AU - Vittrup, Marijke

AU - Sullivan, David A.

PY - 2023/7

Y1 - 2023/7

N2 - Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy. This meeting focused on the impact of glaucoma medications on the ocular surface, and how OSD can influence glaucoma treatment. The term “ocular surface” encompasses the surface (cornea and conjunctiva), tear film, and adnexa (lacrimal and meibomian glands). The speakers included internationally renowned glaucoma and OSD experts. The evidence-based proceedings of this meeting are presented in this TFOS Experts' Meeting report.

AB - Glaucoma is a common disease with an increasing prevalence [1]. Ocular surface disease (OSD) is also common, and its prevalence is increasing [2,3], due in part to the adverse effects of topical glaucoma medications [4,5]. Given this glaucoma/OSD association, David A. Sullivan, MS, PhD (Boston, MA, USA) and Amy Gallant Sullivan (Paris, France) on behalf of the Tear Film & Ocular Surface Society (TFOS), and in collaboration with Miriam Kolko, MD, PhD (Copenhagen University Hospital & University of Copenhagen, Denmark), organized a one-day meeting which was held on Saturday, October 22, in Cernobbio, Italy. This meeting focused on the impact of glaucoma medications on the ocular surface, and how OSD can influence glaucoma treatment. The term “ocular surface” encompasses the surface (cornea and conjunctiva), tear film, and adnexa (lacrimal and meibomian glands). The speakers included internationally renowned glaucoma and OSD experts. The evidence-based proceedings of this meeting are presented in this TFOS Experts' Meeting report.

KW - low vision

KW - glaucoma

KW - medication packaging

U2 - https://doi.org/10.1016/j.jtos.2023.05.012

DO - https://doi.org/10.1016/j.jtos.2023.05.012

M3 - Journal article

SN - 1542-0124

SP - 456

EP - 468

JO - The Ocular Surface

JF - The Ocular Surface

ER -